Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting

Andrea K Miyahira; Jelani C Zarif; Catherine C Coombs; Robert R Flavell; Joshua W Russo; Samir Zaidi; Di Zhao; Shuang G Zhao; Kenneth J Pienta; Howard R Soule

doi:10.1002/pros.24262

Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting

Prostate. 2022 Feb;82(2):169-181. doi: 10.1002/pros.24262. Epub 2021 Nov 3.

Authors

Andrea K Miyahira¹, Jelani C Zarif^{2

3}, Catherine C Coombs⁴, Robert R Flavell^{5

6}, Joshua W Russo⁷, Samir Zaidi⁸, Di Zhao⁹, Shuang G Zhao¹⁰, Kenneth J Pienta¹¹, Howard R Soule¹

Affiliations

¹ Department of Science, Prostate Cancer Foundation, Santa Monica, California, USA.
² Department of Oncology, Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
³ Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Division of Hematology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
⁵ Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.
⁶ Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA.
⁷ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
⁸ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁹ Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
¹⁰ Department of Human Oncology, Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA.
¹¹ The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Abstract

Introduction: The 2021 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Prostate Cancer Research in the 21st Century," was held virtually, from June 24-25, 2021.

Methods: The CHPCA Meeting is organized by the Prostate Cancer Foundation as a unique discussion-oriented meeting focusing on critical topics in prostate cancer research envisioned to bridge the next major advances in prostate cancer biology and treatment. The 2021 CHPCA Meeting was virtually attended by 89 investigators and included 31 talks over nine sessions.

Results: Major topic areas discussed at the meeting included: cancer genomics and sequencing, functional genomic approaches to studying mediators of plasticity, emerging signaling pathways in metastatic castration resistant prostate cancer, Wnt signaling biology and the challenges of targeted therapy, clonal hematopoiesis, neuroendocrine cell plasticity and antitumor immunity, cancer immunotherapy and its synergizers, and imaging the tumor microenvironment and metabolism.

Discussion: This meeting report summarizes the research presented at the 2021 CHPCA Meeting. We hope that publication of this knowledge will accelerate new understandings and the development of new biomarkers and treatments for prostate cancer.

Keywords: cancer immunotherapy; molecular imaging; precision medicine; therapeutics; tumor genomics.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Congresses as Topic
Humans
Immunotherapy / methods*
Male
Prostate* / diagnostic imaging
Prostate* / immunology
Prostate* / metabolism
Prostatic Neoplasms* / genetics
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / therapy
Research / trends

Abstract

Publication types

MeSH terms

Grants and funding